Personal information

No personal information available

Activities

Collapse all

Works (49)

Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status

British Journal of Cancer
2025-03-17 | Journal article
DOI: 10.1038/s41416-025-02966-x
Contributors: Sandro Pignata; Amit Oza; Geoff Hall; Beatriz Pardo; Radoslaw Madry; David Cibula; Jaroslav Klat; Ana Montes; Rosalind Glasspool; Nicoletta Colombo et al.
Source: check_circle
Crossref

Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer

British Journal of Cancer
2024-04-06 | Journal article
DOI: 10.1038/s41416-023-02567-6
Contributors: Shibani Nicum; Naomi McGregor; Rachel Austin; Linda Collins; Susan Dutton; Iain McNeish; Rosalind Glasspool; Marcia Hall; Rene Roux; Agnieszka Michael et al.
Source: check_circle
Crossref

Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10

British Journal of Cancer
2023-01-19 | Journal article
DOI: 10.1038/s41416-022-02022-y
Contributors: Rebecca S. Kristeleit; Yvette Drew; Amit M. Oza; Susan M. Domchek; Susana Banerjee; Rosalind M. Glasspool; Judith Balmaña; Lee-may Chen; Manish R. Patel; Howard A. Burris et al.
Source: check_circle
Crossref

EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)

Future Oncology
2022-10 | Journal article
DOI: 10.2217/fon-2022-0666
Contributors: Panagiotis A Konstantinopoulos; Antonio Gonzalez-Martin; Felipe Melo Cruz; Michael Friedlander; Rosalind Glasspool; Domenica Lorusso; Christian Marth; Bradley J Monk; Jae-Weon Kim; Patsy Hinson et al.
Source: check_circle
Crossref

Microfluidic technologies for immunotherapy studies on solid tumours

Lab on a Chip
2021 | Journal article
DOI: 10.1039/D0LC01305F
Contributors: K. Paterson; S. Zanivan; R. Glasspool; S. B. Coffelt; M. Zagnoni
Source: check_circle
Crossref

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

2016-02 | Journal article
DOI: 10.1093/jnci/djv315
PMID: 26586665
Contributors: Meeks HD; Song H; Michailidou K; Bolla MK; Dennis J; Wang Q; Barrowdale D; Frost D; EMBRACE; McGuffog L et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Evidence of a genetic link between endometriosis and ovarian cancer.

2016-01 | Journal article
DOI: 10.1016/j.fertnstert.2015.09.023
PMID: 26477498
Contributors: Lee AW; Templeman C; Stram DA; Beesley J; Tyrer J; Berchuck A; Pharoah PP; Chenevix-Trench G; Pearce CL; Ovarian Cancer Association Consortium
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.

2015 | Journal article
DOI: 10.1038/ncomms9234
PMID: 26391404
PMC: PMC4580986
Contributors: Lawrenson K; Li Q; Kar S; Seo JH; Tyrer J; Spindler TJ; Lee J; Chen Y; Karst A; Drapkin R et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.

2015 | Journal article
DOI: 10.1371/journal.pone.0128106
PMID: 26091520
PMC: PMC4474865
Contributors: Chornokur G; Lin HY; Tyrer JP; Lawrenson K; Dennis J; Amankwah EK; Qu X; Tsai YY; Jim HS; Chen Z et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.

2015-12 | Journal article
DOI: 10.1002/gepi.21921
PMID: 26399219
PMC: PMC4721602
Contributors: Amankwah EK; Lin HY; Tyrer JP; Lawrenson K; Dennis J; Chornokur G; Aben KK; Anton-Culver H; Antonenkova N; Bruinsma F et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.

2015-12 | Journal article
DOI: 10.1158/1078-0432.CCR-15-0632
PMID: 26152742
Contributors: Johnatty SE; Tyrer JP; Kar S; Beesley J; Lu Y; Gao B; Fasching PA; Hein A; Ekici AB; Beckmann MW et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.

2015-11 | Journal article
DOI: 10.1093/carcin/bgv138
PMID: 26424751
Contributors: Lawrenson K; Iversen ES; Tyrer J; Weber RP; Concannon P; Hazelett DJ; Li Q; Marks JR; Berchuck A; Lee JM et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.

2015-10 | Journal article
DOI: 10.1158/1055-9965.EPI-14-1270
PMID: 26209509
Contributors: Kar SP; Tyrer JP; Li Q; Lawrenson K; Aben KK; Anton-Culver H; Antonenkova N; Chenevix-Trench G; Australian Cancer Study; Australian Ovarian Cancer Study Group et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.

2015-09 | Journal article
DOI: 10.1097/IGC.0000000000000478
PMID: 26067859
Contributors: du Bois A; Reuss A; Pujade-Lauraine E; Pignata S; Ledermann J; Casado A; Sehouli J; Mirza M; Colombo N; Marth C et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Genome-wide significant risk associations for mucinous ovarian carcinoma.

2015-08 | Journal article
DOI: 10.1038/ng.3336
PMID: 26075790
PMC: PMC4520768
Contributors: Kelemen LE; Lawrenson K; Tyrer J; Li Q; Lee JM; Seo JH; Phelan CM; Beesley J; Chen X; Spindler TJ et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.

2015-07 | Journal article
DOI: 10.1093/hmg/ddv101
PMID: 25804953
Contributors: Coetzee SG; Shen HC; Hazelett DJ; Lawrenson K; Kuchenbaecker K; Tyrer J; Rhie SK; Levanon K; Karst A; Drapkin R et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.

2015-07 | Journal article
DOI: 10.1097/IGC.0000000000000446
PMID: 26098090
Contributors: Marth C; du Bois A; Schauer C; du Bois A; Casado A; Vergote I; del Campo JM; Goudopoulou A; Pujade-Lauraine E; Bruchim I et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

2015-05 | Journal article
PMID: 25940428
Contributors: Ovarian Cancer Association Consortium; Breast Cancer Association Consortium; and Consortium of Modifiers of BRCA1 and BRCA2; Hollestelle A; van der Baan FH; Berchuck A; Johnatty SE; Aben KK; Agnarsson BA; Aittomäki K et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.

2015-03 | Journal article
DOI: 10.1016/j.ygyno.2014.12.017
PMID: 25528498
Contributors: Lee AW; Tyrer JP; Doherty JA; Stram DA; Kupryjanczyk J; Dansonka-Mieszkowska A; Plisiecka-Halasa J; Spiewankiewicz B; Myers EJ; Australian Cancer Study (Ovarian Cancer) et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Identification of six new susceptibility loci for invasive epithelial ovarian cancer.

2015-02 | Journal article
DOI: 10.1038/ng.3185
PMID: 25581431
PMC: PMC4445140
Contributors: Kuchenbaecker KB; Ramus SJ; Tyrer J; Lee A; Shen HC; Beesley J; Lawrenson K; McGuffog L; Healey S; Lee JM et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Squamous carcinoma of the ovary.

2014-12 | Journal article
DOI: 10.1007/s11912-014-0413-1
PMID: 25344339
Contributors: Roxburgh P; Glasspool R
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.

2014-11 | Journal article
DOI: 10.1097/IGC.0000000000000289
PMID: 25341576
Contributors: Okamoto A; Glasspool RM; Mabuchi S; Matsumura N; Nomura H; Itamochi H; Takano M; Takano T; Susumu N; Aoki D et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.

2014-11 | Journal article
DOI: 10.1097/IGC.0000000000000297
PMID: 25341588
Contributors: Hasegawa K; Nagao S; Yasuda M; Millan D; Viswanathan AN; Glasspool RM; Devouassoux-Shisheboran M; Covens A; Lorusso D; Kurzeder C et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.

2014-11 | Journal article
DOI: 10.1097/IGC.0000000000000239
PMID: 25341585
Contributors: Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

2014-11 | Journal article
DOI: 10.1097/IGC.0000000000000257
PMID: 25341587
Contributors: Gourley C; Farley J; Provencher DM; Pignata S; Mileshkin L; Harter P; Maenpaa J; Kim JW; Pujaide-Lauraine E; Glasspool RM et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.

2014-11 | Journal article
DOI: 10.1097/IGC.0000000000000249
PMID: 25341579
Contributors: Ray-Coquard I; Brown J; Harter P; Provencher DM; Fong PC; Maenpaa J; Ledermann JA; Emons G; Rigaud DB; Glasspool RM et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.

2014-11 | Journal article
DOI: 10.1097/IGC.0000000000000209
PMID: 25126954
Contributors: Glasspool RM; González Martín A; Millan D; Lorusso D; Åvall-Lundqvist E; Hurteau JA; Davis A; Hilpert F; Kim JW; Alexandre J et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

2014-11 | Journal article
DOI: 10.1097/IGC.0000000000000228
PMID: 25341582
Contributors: Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

2014-11 | Journal article
DOI: 10.1097/IGC.0000000000000264
PMID: 25341586
Contributors: Sagae S; Susumu N; Viswanathan AN; Aoki D; Backes FJ; Provencher DM; Vaughan M; Creutzberg CL; Kurzeder C; Kristensen G et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.

2014-10 | Journal article
DOI: 10.1002/mnfr.201400068
PMID: 25066213
PMC: PMC4197821
Contributors: Kelemen LE; Terry KL; Goodman MT; Webb PM; Bandera EV; McGuire V; Rossing MA; Wang Q; Dicks E; Tyrer JP et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.

2014-04 | Journal article
DOI: 10.1038/bjc.2014.116
PMID: 24642620
PMC: PMC3992493
Contributors: Glasspool RM; Brown R; Gore ME; Rustin GJ; McNeish IA; Wilson RH; Pledge S; Paul J; Mackean M; Hall GD et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancer.

2014-01 | Journal article
DOI: 10.1097/IGC.0000000000000060
PMID: 24356410
Contributors: Roxburgh P; Cowell GW; Glasspool RM
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.

2013 | Journal article
DOI: 10.1038/ncomms2613
PMID: 23535648
PMC: PMC3709460
Contributors: Permuth-Wey J; Lawrenson K; Shen HC; Velkova A; Tyrer JP; Chen Z; Lin HY; Chen YA; Tsai YY; Qu X et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Clear cell carcinoma of ovary and uterus.

2013-12 | Journal article
DOI: 10.1007/s11912-013-0346-0
PMID: 24114188
Contributors: Glasspool RM; McNeish IA
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era.

2013-10 | Journal article
DOI: 10.1097/IGC.0b013e3182a26edb
PMID: 24257568
Contributors: Creutzberg CL; Kitchener HC; Birrer MJ; Landoni F; Lu KH; Powell M; Aghajanian C; Edmondson R; Goodfellow PJ; Quinn M et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.

2012-07 | Journal article
DOI: 10.1097/IGC.0b013e31825736fd
PMID: 22694911
Contributors: Dizon DS; Damstrup L; Finkler NJ; Lassen U; Celano P; Glasspool R; Crowley E; Lichenstein HS; Knoblach P; Penson RT
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Clinical trials in recurrent ovarian cancer.

2011-05 | Journal article
DOI: 10.1097/IGC.0b013e31821bb8aa
PMID: 21543939
Contributors: Friedlander M; Trimble E; Tinker A; Alberts D; Avall-Lundqvist E; Brady M; Harter P; Pignata S; Pujade-Lauraine E; Sehouli J et al.
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.

2008-05 | Journal article
DOI: 10.1093/annonc/mdm606
PMID: 18272913
Contributors: Barrett SV; Paul J; Hay A; Vasey PA; Kaye SB; Glasspool RM; Scottish Gynaecological Cancer Trials Group
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Epigenetic modulation of resistance to chemotherapy?

2007-09 | Journal article
DOI: 10.1093/annonc/mdm415
PMID: 17761701
Contributors: Brown R; Glasspool R
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Epigenetics as a mechanism driving polygenic clinical drug resistance.

2006-04 | Journal article
DOI: 10.1038/sj.bjc.6603024
PMID: 16495912
PMC: PMC2361257
Contributors: Glasspool RM; Teodoridis JM; Brown R
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters.

2005-09 | Journal article
DOI: 10.1158/0008-5472.CAN-05-1715
PMID: 16140922
Contributors: Atkinson SP; Hoare SF; Glasspool RM; Keith WN
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genes.

2005-06 | Journal article
DOI: 10.1593/neo.04766
PMID: 16036112
PMC: PMC1501281
Contributors: Glasspool RM; Burns S; Hoare SF; Svensson C; Keith WN
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Telomerase-directed molecular therapeutics.

2002-04 | Journal article
PMID: 14987378
Contributors: Keith WN; Bilsland A; Evans TR; Glasspool RM
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Clinical significance of transient hyperthyroidism in the course of non-Hodgkin's lymphoma.

2001 | Journal article
PMID: 11554634
Contributors: Glasspool RM; Vasey PA; Peden N
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Telomerase and cancer: time to move from a promising target to a clinical reality.

2001-11 | Journal article
DOI: 10.1002/path.1001
PMID: 11745671
Contributors: Keith WN; Jeffry Evans TR; Glasspool RM
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.

2001-11 | Journal article
DOI: 10.1038/sj.onc.1204954
PMID: 11753658
Contributors: Plumb JA; Bilsland A; Kakani R; Zhao J; Glasspool RM; Knox RJ; Evans TR; Keith WN
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer.

2001-10 | Journal article
DOI: 10.1054/brst.2000.0254
PMID: 14965609
Contributors: Glasspool RM; Twelves CJ
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3.

2000 | Journal article
DOI: 10.1038/sj.neo.7900114
PMID: 11228546
PMC: PMC1508088
Contributors: Zhao JQ; Glasspool RM; Hoare SF; Bilsland A; Szatmari I; Keith WN
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Clinical imaging of cancer metastasis.

2000-08 | Journal article
DOI: 10.1016/S0959-8049(00)00154-4
PMID: 10959052
Contributors: Glasspool RM; Evans TR
Source: Self-asserted source
Rosalind Glasspool via Europe PubMed Central

Peer review (3 reviews for 1 publication/grant)

Review activity for British journal of cancer. (3)
How many people are using ORCID?